* ReShape Lifesciences Inc RSLS.OQ RSLS.O is expected
to show
a fall in quarterly revenue when it reports results on August
15.
* The San Clemente California-based company is expected to
report
a 3.4% decrease in revenue to $3.409 million from $3.53 million
a year ago, according to the mean estimate from 2 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for ReShape
Lifesciences Inc
is for a loss of 36 cents per share. For the same quarter last
year, the company reported a loss of 47 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for ReShape
Lifesciences Inc is $3.08, above its last closing price
of $0.47.
This summary was machine generated August 12 at 22:07 GMT. All
figures in US dollars unless otherwise stated